38.02 USD
-0.23 (-0.6%)
38.02 USD
0 (0%)
Overall CSTL gets a fundamental rating of 5 out of 10. We evaluated CSTL against 100 industry peers in the Health Care Providers & Services industry. While CSTL has a great health rating, there are worries on its profitability. CSTL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CSTL was profitable.
CSTL had a positive operating cash flow in the past year.
CSTL had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CSTL reported negative operating cash flow in multiple years.
1.2 Ratios
CSTL has a Return On Assets of -2.17%. This is comparable to the rest of the industry: CSTL outperforms 41.00% of its industry peers.
CSTL has a Return On Equity (-2.62%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| ROIC | N/A |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of CSTL has remained more or less at the same level.
CSTL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 79.94%, CSTL belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CSTL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CSTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.94% |
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSTL has more shares outstanding
Compared to 5 years ago, CSTL has more shares outstanding
CSTL has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.50 indicates that CSTL is not in any danger for bankruptcy at the moment.
CSTL's Altman-Z score of 7.50 is amongst the best of the industry. CSTL outperforms 93.00% of its industry peers.
The Debt to FCF ratio of CSTL is 0.41, which is an excellent value as it means it would take CSTL, only 0.41 years of fcf income to pay off all of its debts.
CSTL has a better Debt to FCF ratio (0.41) than 92.00% of its industry peers.
CSTL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CSTL's Debt to Equity ratio of 0.02 is amongst the best of the industry. CSTL outperforms 82.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Altman-Z | 7.5 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
A Current Ratio of 6.47 indicates that CSTL has no problem at all paying its short term obligations.
The Current ratio of CSTL (6.47) is better than 96.00% of its industry peers.
A Quick Ratio of 6.31 indicates that CSTL has no problem at all paying its short term obligations.
The Quick ratio of CSTL (6.31) is better than 96.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.31 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.00% over the past year.
The Earnings Per Share has been growing by 29.69% on average over the past years. This is a very strong growth
CSTL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.15%.
CSTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.95% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-125%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-3.19%
3.2 Future
The Earnings Per Share is expected to decrease by -17.28% on average over the next years. This is quite bad
Based on estimates for the next years, CSTL will show a small growth in Revenue. The Revenue will grow by 6.51% on average per year.
EPS Next Y-281.8%
EPS Next 2Y-107.44%
EPS Next 3Y-50.14%
EPS Next 5Y-17.28%
Revenue Next Year1.09%
Revenue Next 2Y0.09%
Revenue Next 3Y4.42%
Revenue Next 5Y6.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 146.23, the valuation of CSTL can be described as expensive.
CSTL's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of CSTL to the average of the S&P500 Index (26.59), we can say CSTL is valued expensively.
The Forward Price/Earnings Ratio is negative for CSTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 146.23 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSTL is valued a bit more expensive than the industry average as 63.00% of the companies are valued more cheaply.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CSTL is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.73 | ||
| EV/EBITDA | 81.41 |
4.3 Compensation for Growth
CSTL's earnings are expected to decrease with -50.14% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)4.93
EPS Next 2Y-107.44%
EPS Next 3Y-50.14%
5. Dividend
5.1 Amount
No dividends for CSTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
38.02
-0.23 (-0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners90.57%
Inst Owner Change-3.52%
Ins Owners2.48%
Ins Owner Change-3.61%
Market Cap1.11B
Revenue(TTM)343.53M
Net Income(TTM)-12.24M
Analysts88.57
Price Target38.51 (1.29%)
Short Float %5.89%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.17%
Min EPS beat(2)96.25%
Max EPS beat(2)128.1%
EPS beat(4)3
Avg EPS beat(4)151.85%
Min EPS beat(4)-175.74%
Max EPS beat(4)558.79%
EPS beat(8)7
Avg EPS beat(8)149.84%
EPS beat(12)10
Avg EPS beat(12)106.51%
EPS beat(16)13
Avg EPS beat(16)87.37%
Revenue beat(2)2
Avg Revenue beat(2)16.33%
Min Revenue beat(2)14.33%
Max Revenue beat(2)18.34%
Revenue beat(4)4
Avg Revenue beat(4)10.84%
Min Revenue beat(4)3.31%
Max Revenue beat(4)18.34%
Revenue beat(8)8
Avg Revenue beat(8)11.87%
Revenue beat(12)12
Avg Revenue beat(12)11.82%
Revenue beat(16)16
Avg Revenue beat(16)10.9%
PT rev (1m)5.96%
PT rev (3m)5.96%
EPS NQ rev (1m)2.83%
EPS NQ rev (3m)31.25%
EPS NY rev (1m)37.96%
EPS NY rev (3m)38.5%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)4.75%
Revenue NY rev (1m)4.24%
Revenue NY rev (3m)5.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 146.23 | ||
| Fwd PE | N/A | ||
| P/S | 3.23 | ||
| P/FCF | 43.73 | ||
| P/OCF | 17.96 | ||
| P/B | 2.38 | ||
| P/tB | 3.04 | ||
| EV/EBITDA | 81.41 |
EPS(TTM)0.26
EY0.68%
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)0.87
FCFY2.29%
OCF(TTM)2.12
OCFY5.57%
SpS11.77
BVpS16
TBVpS12.51
PEG (NY)N/A
PEG (5Y)4.93
Graham Number9.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.94% | ||
| FCFM | 7.39% |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
F-Score4
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 85.13% | ||
| Cap/Sales | 10.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 789.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.31 | ||
| Altman-Z | 7.5 |
F-Score4
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)113.65%
Cap/Depr(5y)290.73%
Cap/Sales(3y)6.28%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-125%
EPS Next Y-281.8%
EPS Next 2Y-107.44%
EPS Next 3Y-50.14%
EPS Next 5Y-17.28%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-3.19%
Revenue Next Year1.09%
Revenue Next 2Y0.09%
Revenue Next 3Y4.42%
Revenue Next 5Y6.51%
EBIT growth 1Y-3265.41%
EBIT growth 3YN/A
EBIT growth 5Y3.5%
EBIT Next Year571.08%
EBIT Next 3Y-53.98%
EBIT Next 5Y-26.67%
FCF growth 1Y160.68%
FCF growth 3YN/A
FCF growth 5Y43.14%
OCF growth 1Y304.51%
OCF growth 3YN/A
OCF growth 5Y56%
CASTLE BIOSCIENCES INC / CSTL FAQ
What is the fundamental rating for CSTL stock?
ChartMill assigns a fundamental rating of 5 / 10 to CSTL.
What is the valuation status for CSTL stock?
ChartMill assigns a valuation rating of 1 / 10 to CASTLE BIOSCIENCES INC (CSTL). This can be considered as Overvalued.
Can you provide the profitability details for CASTLE BIOSCIENCES INC?
CASTLE BIOSCIENCES INC (CSTL) has a profitability rating of 3 / 10.
What is the valuation of CASTLE BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CASTLE BIOSCIENCES INC (CSTL) is 146.23 and the Price/Book (PB) ratio is 2.38.
How financially healthy is CASTLE BIOSCIENCES INC?
The financial health rating of CASTLE BIOSCIENCES INC (CSTL) is 8 / 10.